Risk factor
Meaningful price volatility
Profitability factor
Good margins and returns
About
Headquartered in Beijing, China, Tibet AIM Pharm. Inc. was established in 2003 to conduct research and develop medical products across China. The company's diverse pharmaceutical portfolio targets a range of health conditions. Among its offerings are Miglitol tablets for managing diabetes and Gualoupi injection, prescribed for coronary disease. It also provides Oxytocin injection for gynecological and obstetric applications, alongside Carbetocin injections. A significant product is NalMefene injection, which is employed for treating various acute toxicities, such as those from alcohol, organic phosphorus, carbon monoxide, sedative-hypnotics, and opioid substances. Furthermore, it is indicated for serious infections, shock, syncope, and certain neurological issues. Completing its product line are Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, with therapeutic areas also extending to anti-infective, anti-allergic, and digestive system treatments.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, 'expensi